ライフサイエンスコーパス: Agilent

1 m designed to query CNVs at high resolution (Agilent).

2 rray platforms from Affymetrix, Illumina and Agilent.

3 arative genomic hybridization using a custom Agilent 1 M oligonucleotide array intended to cover 197

4 of our electroosmotic (EO)-driven HPLC with Agilent 1200 HPLC; comparable efficiencies, resolutions,

5 this report, we implemented the method on an Agilent 1290 Infinity II LC system equipped with a Multi

6 he onset of hypoxia was analysed using ovine Agilent 15.5k array and validated with qPCR and immunohi

7 genetic basis of this obesity syndrome using Agilent 185 k array comparative genomic hybridization (a

8 The Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alt

9 acted explosives were then analyzed with the Agilent 2100 Bioanalyzer lab on a chip device with minim

10 ulfite restriction analysis coupled with the Agilent 2100 Bioanalyzer platform), as a novel approach

11 urine sediments was also assessed using the Agilent 2100 Bioanalyzer.

12 LabChip-based plasmid assay that runs on the Agilent 2100 Bioanalyzer.

13 Human Gene 1.0ST-Array = 61, Illumina = 52, Agilent 4 x 44 K = 60).

14 from 17 tumors which were examined using the Agilent 44 k whole genome microarray.

15 Transthoracic power modulation images (Agilent 5500) were obtained during continuous intravenou

16 mAb (vedolizumab) from ~400 samples using an Agilent 6545XT AdvanceBio Q-TOF at the University of Ore

17 All-Ions (Q-RAI) acquisition function on the Agilent 6546 quadrupole time-of-flight (Q-TOF) mass spec

18 this report, we describe modifications to an Agilent 6560 drift tube ion mobility-mass spectrometer i

19 we employed three different IM-MS platforms (Agilent 6560 IM-QToF, Waters Synapt G2, and a home-built

20 cross three IM-MS configurations, namely, an Agilent 6560 IMQToF, a Waters Synapt G2 possessing a TWI

21 for a commercially available drift tube IMS (Agilent 6560 with high-resolution demultiplexing, HRdm)

22 ross two instrument platforms (Waters G2 and Agilent 6560), with both producing similar abilities to

23 eries capillary columns housed in a standard Agilent 6890 gas chromatograph fitted with a high data a

24 from 11 different tumour types, profiled on Agilent, Affymetrix platforms or based on RNA sequencing

25 e impact of eight normalizations across both Agilent and Affymetrix expression platforms on three exp

26 ance of CNA detection by two high-resolution Agilent and Affymetrix microarray platforms.

27 Affymetrix and Illumina SNP array data with Agilent and fosmid clone end-sequencing results on eight

28 Agilent and Illumina are able to detect a greater total

29 ice with two different microarray platforms (Agilent and Illumina).

30 on of the three major platforms--Affymetrix, Agilent and Illumina.

31 atforms (the Mx3000P qPCR system [Stratagene-Agilent] and the 7500 real-time PCR system [ABI Life Tec

32 to and imports the native output files from Agilent, Applied Biosystems, Thermo Fisher Scientific an

33 we developed automated methods employing the Agilent AssayMAP Bravo microchromatography platform and

34 Results from IHC, PCR, RT-PCR, RNA Agilent Bioanalyser and Real-Time PCR showed that a nove

35 RNA integrity as assessed by Agilent Bioanalyzer, and amplification of the 28S riboso

36 The procedure used for Agilent Bond Elut DMS showed higher recoveries than the

37 rds was also performed (Whatman FTA DMPK and Agilent Bond Elut DMS) using elution procedures recommen

38 predisposition were captured using the BROCA Agilent cancer risk panel followed by massively parallel

39 m Affymetrix GeneChips (MAS5/GCOS or dChip), Agilent Catalog or Custom arrays (using Agilent's Featur

40 cancer cell line derived RNA aliquots using Agilent cDNA and Affymetrix oligonucleotide microarray p

41 device compatible with injection systems of Agilent CE instruments is proposed, which consists of a

42 We applied this technology by coupling an Agilent Chemstation high-performance liquid chromatograp

43 ms, including strand-specific tiling arrays, Agilent custom expression arrays, strand-specific RNA-se

44 minant TCGA-cohorts (Affymetrix U133A = 548, Agilent Custom-Array = 588, RNA-seq = 168), and three As

45 a range of model systems-IMS CCS standards (Agilent ESI Tune Mix), the monomeric protein Ubiquitin (

46 After adjusting Affymetrix data to mimic the Agilent experimental design (reference sample effect), w

47 Rainwater was analysed after treatment using Agilent GC-FID.

48 ylation arrays [CHARM]) and gene expression (Agilent gene expression arrays) in 94 patients with IPF

49 ric patients and to test the accuracy of the Agilent Heartstream FR2 Patient Analysis System for sens

50 phic analysis (< 21 min) was performed in an Agilent HP-5MS column under programmed temperature condi

51 ailed sample preparation protocols, using an Agilent HPLC system, are described for Lys-C digestion o

52 This device works together with an Agilent HPLC-Chip to perform high-throughput nanoflow li

53 r commercial exome sequencing platforms from Agilent, Illumina and Nimblegen applied to the same huma

54 HT-12v3 from Illumina, Inc.; and 4112A from Agilent, Inc.

55 designed by our group and manufactured using Agilent inkjet technology.

56 during the spray ionization process using an Agilent jet stream (AJS) ion source with a digestion eff

57 Despite the larger design region of the Agilent kit, we find that the Illumina kit performs bett

58 The Agilent kits exhibit less precision than the ND-1000 spe

59 However, the Agilent kits require 1 microl of sample and can determin

60 lysis steps by implementing an iChemExplorer/Agilent LC-MS instrument as our reactor and analysis too

61 used whole-genome transcript profiling using Agilent long-oligonucleotide microarrays representing 12

62 as UniDec and an implementation of MaxEnt in Agilent MassHunter BioConfirm.

63 ere collected and RNA was analyzed using the Agilent microarray platform.

64 mbl transcripts mapped by Affymetrix(R); and Agilent microarray probes.

65 cular roles of Interferons on tumor, and the Agilent microarrays carrying tens of thousands of total

66 erated a wholly defined spike-in dataset for Agilent microarrays consisting of 12 arrays with more th

67 adult male C57Bl/6j mice were profiled with Agilent microarrays to identify the differences responsi

68 unohistochemical markers (n = 727 women) and Agilent microarrays, for MammaPrint risk scoring (n = 65

69 pression in blood from individual mice using Agilent microarrays.

70 a and their transcriptome was analyzed using Agilent microarrays.

71 small RNA libraries and hybridization-based Agilent microarrays.

72 ted and genomic profiling was done using 22k Agilent microarrays.

73 croRNA expression profiles were generated by Agilent microRNA arrays.

74 Parallel analysis of microRNA with the Agilent miRNA microarray platform revealed that miR-142-

75 SCD = 7, controls = 7) by hybridizing to the Agilent miRNA microarrays.

76 In comparison, ion trap noise from Agilent MSD-Trap-SL is larger than the Q-TOF noise and i

77 etric approach has been used to optimize the Agilent multimode ion source.

78 Agilent normal reference Sample B can be admixed with Sa

79 This method uses the Agilent OFFGEL 3100 Fractionator and was optimized to pr

80 ated with Affymetrix 250K SNP arrays or 244K Agilent oligo-arrays and tested for inheritance from the

81 6J, DBA/2J, B6D2F1, and 37 BXD strains using Agilent oligonucleotide microarrays.

82 Data were collected using a custom designed Agilent oligonucleotide.

83 rray comparative genomic hybridization using Agilent platform, transcriptome sequencing using HiSeq 2

84 ree methods for the low-resolution data from Agilent platform.

85 NimbleGen and Agilent platforms outperformed Illumina and Affymetrix i

86 en results obtained using the Affymetrix and Agilent platforms.

87 which are not targeted by the Nimblegen and Agilent platforms.

88 si muscle gene expression was analyzed using Agilent porcine transcriptome microarrays and clusters o

89 It is integrated with an Agilent qTOF MS where the collision cell was replaced wi

90 bitrap "exactive" (QE) mass spectrometers by Agilent (QTOF), Bruker (QTOF), SCIEX (QTOF), Waters (QTO

91 tography, we acquired data in parallel on an Agilent RapidFire system and compared the screening resu

92 range via an ND-1000 spectrophotometer (UV), Agilent RNA 6000 kits (MCE), and Quant-iT RiboGreen assa

93 platforms-three hybridization capture-based (Agilent, Roche and Illumina) and two reduced-representat

94 Our analyses concluded that the Agilent's 60-mer oligonucleotide microarray with probe d

95 DNA- and RNA-sample quality control, such as Agilent's Bioanalyzer(R) and TapeStation(R) products, ar

96 ip), Agilent Catalog or Custom arrays (using Agilent's Feature Extraction software) or data created b

97 tional exome capture technologies, including Agilent's SureSelect and NimbleGen's SeqCap, to generate

98 The Agilent Seahorse machine is a common method to measure r

99 is limitation, we present here a new method, Agilent SureSelect (XT HS) target enrichment, which can

100 two kits, the Illumina TruSight One and the Agilent SureSelect Focused Exome.

101 formed in 2 cousins in this family using the Agilent SureSelect Human all Exon 51 Mb version 5 captur

102 The genomic DNA was captured with the Agilent SureSelect Human All Exon kit, sequenced on the

103 a new oculome panel using a custom-designed Agilent SureSelect QXT target capture method (Agilent Te

104 Exome capture was performed by Agilent SureSelect V4, and sequencing was performed usin

105 We used the Agilent SureSelect XT2 protocol for library preparation,

106 a capillary electrophoresis device (7100 CE Agilent system) in the pressurization mode with in situ

107 sis of libraries of long oligonucleotides on Agilent Technologies' SurePrint DNA microarray platform.

108 es by immunohistochemistry (73-10 RUO assay, Agilent Technologies) and digital pathology.

109 roarrays were the platforms from Affymetrix, Agilent Technologies, Applied Biosystems, GE Healthcare,

110 Mandecki), and QuikChange (Agilent Technologies, La Jolla, CA).

111 was analyzed using 22,000-gene microarrays (Agilent Technologies, Palo Alto, CA).

112 The Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, Calif.) utilizes capill

113 gilent SureSelect QXT target capture method (Agilent Technologies, Santa Clara, CA) to capture and pe

114 C3 immunohistochemistry pharmDx assay; Dako, Agilent Technologies, Santa Clara, CA, USA) recurrent or

115 interaction liquid chromatography as well as Agilent, Thermo Scientific, AB SCIEX, and LECO mass spec

116 by hybridizing petunia samples to a 4 x 44 K Agilent tomato array.

117 mobility (HRIM) separation were achieved for Agilent tune mix ions through a ~12.8 m serpentine separ

118 calibration curves for the arrival times of Agilent Tune Mix ions.

119 ( approximately 340 vs approximately 10) for Agilent tuning mix m/z 622 and 922 ions was achieved for

120 IMS-MS relative to a drift tube IMS-MS using Agilent tuning mixture cations and tetraalkylammonium ca

121 igh resolution separations were achieved for Agilent tuning mixture phosphazene ions over a broad mob

122 bration errors for the three calibrant sets (Agilent tuning mixture, polyalanine, and one assembled i

123 .5 and acetonitrile in a gradient mode on an Agilent Zorbax Bonus RP RRHD 100 x 2.1 mm and 1.8 um col

124 cs of three chromatographic silica products: Agilent Zorbax SB300, Waters Symmetry 300, and Merck Chr